BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31152491)

  • 1. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis.
    Trachtenberg BH; Kamble RT; Rice L; Araujo-Gutierrez R; Bhimaraj A; Guha A; Park MH; Hussain I; Bruckner BA; Suarez EE; Victor DW; Adrogue HE; Baker KR; Estep JD
    Am J Transplant; 2019 Oct; 19(10):2900-2909. PubMed ID: 31152491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.
    Gillmore JD; Goodman HJ; Lachmann HJ; Offer M; Wechalekar AD; Joshi J; Pepys MB; Hawkins PN
    Blood; 2006 Feb; 107(3):1227-9. PubMed ID: 16210334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.
    Dey BR; Chung SS; Spitzer TR; Zheng H; Macgillivray TE; Seldin DC; McAfee S; Ballen K; Attar E; Wang T; Shin J; Newton-Cheh C; Moore S; Sanchorawala V; Skinner M; Madsen JC; Semigran MJ
    Transplantation; 2010 Oct; 90(8):905-11. PubMed ID: 20733534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
    Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.
    Gray Gilstrap L; Niehaus E; Malhotra R; Ton VK; Watts J; Seldin DC; Madsen JC; Semigran MJ
    J Heart Lung Transplant; 2014 Feb; 33(2):149-56. PubMed ID: 24200511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea.
    Kim SJ; Lee GY; Jang HR; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2013 Dec; 20(4):204-11. PubMed ID: 23914780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors in light chain amyloidosis].
    Jávorniczky NR; Bodó I; Masszi T; Mikala G
    Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation.
    Di Nora C; Sponga S; Ferrara V; Patriarca F; Fanin R; Nalli C; Lechiancole A; Vendramin I; Livi U
    J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):261-267. PubMed ID: 33633041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
    Badar T; Cornelison AM; Shah ND; Bashir Q; Parmar S; Patel K; Hosing C; Popat U; Weber DM; Thomas SK; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Eur J Haematol; 2016 Oct; 97(4):342-7. PubMed ID: 26773409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
    Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
    Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and autologous stem cell transplantation hematopoietic in patients with AL amyloidosis.
    Carretero M; Villanueva E; Brulc EB; Faelo FM; Aguirre MA; Pérez-de-Arenaza D; Belziti CA; Arbelbide JA; Nucifora EM; Posadas-Martinez ML
    Arch Cardiol Mex; 2023; 93(4):435-441. PubMed ID: 37972368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.